mCRPC: Assessing Progression from Asymptomatic to Symptomatic Disease
September 30, 2014
mCRPC: Progression from Asymptomatic to Symptomatic Disease and Approaches to Patient Treatment
A review of radium-223 in the newly symptomatic mCRPC patient. The mechanism of action and radium-223 pivotal trial results are discussed. The assessment of treatment response with radium-223 is illustrated in this patient case study.
Alicia K. Morgans, MD
Vanderbilt Ingram Cancer Center - University Medical Center, Divison of Hematology/Oncology
Dr. Morgans specializes in the treatments of genitourinary malignancies, including cancers of the prostate, bladder, testis (germ cell) and penis.